Homotypic protection against influenza in a pediatric cohort in Managua, Nicaragua.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 03 2022
04 03 2022
Historique:
received:
28
09
2021
accepted:
16
02
2022
entrez:
5
3
2022
pubmed:
6
3
2022
medline:
14
4
2022
Statut:
epublish
Résumé
The period of protection from repeat infection following symptomatic influenza is not well established due to limited availability of longitudinal data. Using data from a pediatric cohort in Managua, Nicaragua, we examine the effects of natural influenza virus infection on subsequent infection with the same influenza virus subtype/lineage across multiple seasons, totaling 2,170 RT-PCR-confirmed symptomatic influenza infections. Logistic regression models assessed whether infection in the prior influenza season protected against homologous reinfection. We sequenced viruses from 2011-2019 identifying dominant clades and measuring antigenic distances between hemagglutinin clades. We observe homotypic protection from repeat infection in children infected with influenza A/H1N1pdm (OR 0.12, CI 0.02-0.88), A/H3N2 (OR 0.41, CI 0.24-0.73), and B/Victoria (OR 0.00, CI 0.00-0.14), but not with B/Yamagata viruses (OR 0.60, CI 0.09-2.10). Overall, protection wanes as time or antigenic distance increases. Individuals infected with one subtype or lineage of influenza virus have significantly lower odds of homologous reinfection for the following one to two years; after two years this protection wanes. This protection is demonstrated across multiple seasons, subtypes, and lineages among children.
Identifiants
pubmed: 35246548
doi: 10.1038/s41467-022-28858-9
pii: 10.1038/s41467-022-28858-9
pmc: PMC8897407
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI044616
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI149747
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI088654
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Am J Epidemiol. 1987 Apr;125(4):576-86
pubmed: 3826038
Elife. 2020 Jul 07;9:
pubmed: 32633233
Immunity. 2017 Oct 17;47(4):599-603
pubmed: 29045889
Nat Commun. 2021 Jul 14;12(1):4313
pubmed: 34262041
Expert Rev Vaccines. 2017 Jul;16(7):1-14
pubmed: 28562111
Virol J. 2018 Jan 19;15(1):17
pubmed: 29370862
Dev Biol Stand. 1977 Jun 1-3;39:149-54
pubmed: 342306
BMC Infect Dis. 2014 Jul 28;14:414
pubmed: 25066592
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
Nat Commun. 2020 Sep 11;11(1):4566
pubmed: 32917903
PLoS One. 2019 Sep 12;14(9):e0222381
pubmed: 31513690
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1701-9
pubmed: 26951657
Lancet Respir Med. 2014 Jun;2(6):445-54
pubmed: 24717637
Annu Rev Microbiol. 1983;37:529-49
pubmed: 6357060
Vaccines (Basel). 2018 May 21;6(2):
pubmed: 29883414
Nat Commun. 2019 Apr 10;10(1):1660
pubmed: 30971703
J Gen Virol. 1991 Mar;72 ( Pt 3):699-703
pubmed: 2005435
Am J Respir Crit Care Med. 2015 Jun 15;191(12):1422-31
pubmed: 25844934
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
J Med Virol. 1983;12(1):17-23
pubmed: 6619811
PLoS Pathog. 2014 Aug 21;10(8):e1004310
pubmed: 25144780
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
JAMA. 1974 Jan 14;227(2):164-9
pubmed: 4357298
Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):17221-17227
pubmed: 32631992
Emerg Infect Dis. 2018 Aug;24(8):1536-1540
pubmed: 30015611
BMC Infect Dis. 2018 Jun 8;18(1):269
pubmed: 29884140
Elife. 2014;3:e01914
pubmed: 24497547
Scand J Immunol. 2016 Mar;83(3):165-73
pubmed: 26715418
BMC Infect Dis. 2015 Nov 09;15:504
pubmed: 26553094
Immunol Cell Biol. 2012 Feb;90(2):149-58
pubmed: 21647170
Hum Vaccin. 2008 Nov-Dec;4(6):420-4
pubmed: 18535408
Vaccine. 2011 Oct 6;29(43):7524-8
pubmed: 21820476
Arch Virol. 1987;92(1-2):121-33
pubmed: 3800656
Nature. 2015 Jul 9;523(7559):217-20
pubmed: 26053121
Curr Epidemiol Rep. 2018;5(1):1-9
pubmed: 29503792
J Infect Dis. 2006 Jan 1;193(1):49-53
pubmed: 16323131
Elife. 2015 Jan 16;4:e05055
pubmed: 25594904
Am J Epidemiol. 1969 Aug;90(2):162-9
pubmed: 5804363
Nat Rev Immunol. 2019 Jun;19(6):383-397
pubmed: 30837674
Curr Opin Virol. 2017 Feb;22:105-111
pubmed: 28088686
Clin Infect Dis. 2014 Aug 15;59(4):517-24
pubmed: 24825868